Frankfurt - Delayed Quote EUR

Boston Scientific Corporation (BSX.F)

68.00 -1.00 (-1.45%)
At close: April 26 at 4:53 PM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Michael F. Mahoney Chairman, President & CEO 4.51M 12.1M 1965
Mr. Daniel J. Brennan Executive VP & CFO 2M 1.6M 1966
Mr. Joseph M. Fitzgerald Executive VP & Group President of Cardiology 1.71M 4.38M 1964
Mr. Jeffrey B. Mirviss Executive VP & President of Peripheral Interventions 1.34M -- 1966
Mr. Arthur Crosswell Butcher Executive VP and Group President of MedSurg & Asia Pacific 1.39M 583.58k 1971
Mr. David J. Roux Independent Director 125.84k -- 1957
Mr. John Bradley Sorenson Executive Vice President of Global Operations -- -- 1968
Ms. Emily Woodworth Senior VP, Global Controller & Chief Accounting Officer -- -- 1978
Ms. Jodi Euerle Eddy Senior VP and Chief Information & Digital Officer -- -- 1974
Mr. Jonathan R Monson Senior VP of Investor Relations -- -- --

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000 https://www.bostonscientific.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
48,000

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Boston Scientific Corporation’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Jul 25, 2024 - Jul 29, 2024
Boston Scientific Corporation Earnings Call